Navigating the complexities of the NSCLC treatment pathway: A focus on antibody-drug conjugates

touchPANEL DISCUSSION for touchONCOLOGY Listen to a panel of leading experts discuss the emerging role of antibody-drug conjugates (ADCs) in the treatment of patients with non-small cell lung cancer (NSCLC), including the mechanistic rationale and role of biomarkers in patient selection, the latest efficacy and safety data, and dose-finding strategies for optimal use in NSCLC.  The experts: Prof. Jarushka Naidoo, Beaumont RCSI Cancer Centre, Dublin, Ireland Dr Rebecca Heist, Massachusetts General Hospital Cancer Center, Boston, MA, USA Dr Antonio Passaro, European Institute of Oncology, Milan, Italy This touchPODCAST is for HCPs only.  This activity is funded by an independent medical education grant from AstraZeneca. This activity is provided by touchIME.  For further information please visit: https://touchoncology.com/education/pd-navigating-the-nsclc-treatment-pathway-focus-on-adcs/